Edesa Biotech reports exploratory data showing 32% lower 28-day mortality with paridiprubart in AKI patients with respiratory distress

• Edesa Biotech disclosed new exploratory analyses of completed ARDS studies, highlighting benefits for paridiprubart in patients with acute kidney injury.
• The analysis has already been presented in an oral session at the 63rd European Renal Association Congress.
• Results pointed to improved survival signals versus placebo, supported by better kidney-related outcomes in the high-risk subgroup.
• Safety in the acute kidney injury subgroup looked consistent with prior experience, with no meaningful imbalance in overall adverse events.
• Data are hypothesis-generating, positioning paridiprubart for potential AKI-focused trials while supporting its broader ARDS development strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050920PRIMZONEFULLFEED9732293) on June 05, 2026, and is solely responsible for the information contained therein.